MarketPeel
Insider Trading Intelligence
CA

Christophe Arbet-engels

XFOR
CHIEF MEDICAL OFFICER · X4 PHARMACEUTICALS, INC · CIK 0001802615
FILING MIX · LIFETIME88%/12%
BUYS
7
SELLS
1
TOTAL VALUE
$1.61M
COMPANIES
2
ACTIVE SINCE
Aug 2023
HOLDINGS NOW
1,014,207
AVG SELL PX
$0.45
TRADE KIND
SHOWING 8 / 8
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Christophe Arbet-engels, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%+46.62%-1.01%+47.63%+47.63%
14d1+0.00%+10.87%-1.18%+12.05%+12.05%
30d1+100.00%-5.67%-1.77%-3.90%-3.90%
60d1+100.00%-45.67%-5.06%-40.61%-40.61%
90d1+100.00%-60.84%-9.81%-51.03%-51.03%
180d1+100.00%-89.53%+4.63%-94.16%-94.16%
1y1+100.00%-74.17%+13.71%-87.88%-87.88%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XFOR · 864,207 shares · as of Feb 12, 2025
0312,500625,000937,5001,250,00020242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
FLOW · 7 buys / 1 sellsCOVERAGE · 10 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALT
ALTIMMUNE, INC.
PURCHASEGRANT
Stock grant
450,000450,000Oct 1, 2025Oct 3, 2025View →
ALT
ALTIMMUNE, INC.
PURCHASEGRANT
Stock grant
150,000150,000Oct 1, 2025Oct 3, 2025View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
850,000864,207Feb 12, 2025Feb 14, 2025View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Medical Officer
11,624$0.45$5.3K14,207Jan 24, 2025Jan 27, 2025View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
25,83125,831Jan 23, 2025Jan 27, 2025View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
475,831475,831Feb 13, 2024Feb 16, 2024View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
180,816180,816Feb 13, 2024Feb 28, 2024View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
1,250,000$1.28$1.60M1,250,000Aug 31, 2023Sep 5, 2023View →
Other insiders · XFOR
Loading peer insiders…
About this filer
CIK 0001802615
ROLE
Chief Medical Officer
PRIMARY
XFOR
COMPANIES
2
ACTIVE SINCE
Aug 2023
MARKETPEEL · /INSIDER/0001802615DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback